Clinical trials: PET-CT
Prostate Cancer
[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer.
- Trial name
- PROPET (NCT00670527)
- Testing
- [18F] Fluorocholine PET/CT
- Where
- Denmark
- Volunteers
- 205 people
- Sponsor
- Odense University Hospital
Neuroendocrine Tumors
Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
This study is testing a new PET/CT scan that uses a special tracer called [⁶⁸Ga]Ga-DLL3 nanobody to see if it can better detect cancer spread (metastases) in people with neuroendocrine tumors than the standard scans currently…
- Trial name
- DSC-NEC (NCT07733024)
- Testing
- 68Ga-PFD3
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Tingting Yuan
Cancer
Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection
Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been demonstrated to outperform other imaging modalities such as CT and magnetic resonance imaging (MRI) for the detection of metastatic…
- Trial name
- NCT05513027
- Testing
- Augmented Whole-body Scanning via Magnifying PET, PET/CT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Prostate Adenocarcinoma
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing…
- Trial name
- NCT03762759
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Cancer, Malignant Neoplasm
A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors
The investigators designed and synthesized a novel fibroblast activation protein (FAP) ligand (DOTA-GPFAPI-04) by assembling three functional moieties: a quinoline-based FAP inhibitor for specifically targeting FAP, a FAP…
- Conditions
- Cancer, Malignant Neoplasm, Tumors, Metastatic Cancer
- Trial name
- 68Ga-GPFAPI (NCT06186427)
- Testing
- 68Ga-DOTA-GPFAPI-04 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
SAPHO Syndrome
Characterizing SAPHO With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation.
- Trial name
- NCT04596462
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate…
- Trial name
- THUNDER (NCT06282588)
- Testing
- Darolutamide, Radiotherapy, Zoladex 3.6Mg Implant
- Where
- 9 sites in Belgium
- Volunteers
- 493 people
- Sponsor
- Cancer Research Antwerp
Breast Cancer, Lung Cancer
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging of tissue factor (TF) expression. The tracer has the potential of identifying tumors with high levels of TF expression, which is expected…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT03790423
- Testing
- Injection of 18F-ASIS, PET/CT scan
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Invasive Fungal Infections
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
- Trial name
- SPECIFIC (NCT06105411)
- Testing
- 68Ga-labelled TAFC PET/CT scan
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
HIV, Inflammation
PET/CT Imaging Companion Study To ACTG A5314
HIV-infected individuals on antiretroviral therapy (ART) are at increased risk for cardiovascular disease (CVD), likely due to chronically increased inflammation.
- Conditions
- HIV, Inflammation, Atherosclerosis
- Trial name
- PET/CTMTX (NCT02312219)
- Testing
- Folic Acid, Low Dose Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Renal Uptake at F-18-FDG PET/CT
Kidney Uptake at F-18 FDG PET/CT Studies and Renal Function Status
Searching for a possible correlation between renal uptake at F-18-FDG PET/CT and renal functional parameters in both normal subjects and patients with CKD.
- Trial name
- NCT06268067
- Testing
- PET/CT
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer
Early Lung Cancer Detection in High Risk Individuals
The MILD project is a randomized lung cancer screening trial whose primary aim is to evaluate the impact on mortality of early lung cancer detection through LDCT (low-dose computed tomography) in 2 groups: a control group…
- Trial name
- MILD (NCT02837809)
- Testing
- Low dose CT
- Where
- Italy
- Volunteers
- 4,099 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging Studies and the Development of Multiple Myeloma
Background: Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01571726
- Testing
- Fluciclatide
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer
The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed…
- Trial name
- PROSPETMR2021 (NCT05582876)
- Testing
- Radiopharmaceutical 68Ga-PSMA-11 PET/CT
- Where
- 7 sites in Poland
- Volunteers
- 366 people
- Sponsor
- Medical University of Bialystok
Crohn's Disease
PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease
The costs and potential complications (side effects) of therapies currently used to treat Crohn's disease could be reduced if a non-invasive test existed that determined which therapies benefit patients and which do not.
- Trial name
- NCT01759017
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Cancer of Head and Neck
Prognostic Value of 18FDG PET/CT Textural Indices in HNSCC
Head and neck (HN) cancer is the sixth most common malignancy worldwide, with around 800,000 new cases and 320,000 deaths in 2015.
- Trial name
- ImpactTextureO (NCT03378193)
- Where
- France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Brest
Non Small Cell Lung Cancer (NSCLC)
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
Stereotactic body radiotherapy (SBRT) has emerged as one of the leading curative method for early stage non-small cell lung cancer (NSCLC).
- Trial name
- SBRT FLT-PET (NCT02456246)
- Testing
- FLT-PET
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to…
- Conditions
- Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage, Primary Myelofibrosis, Prefibrotic Stage, Polycythemia Vera
- Trial name
- NCT03121599
- Testing
- Diagnostic (18F-FLT PET/CT)
- Where
- Qatar
- Volunteers
- 3 people
- Sponsor
- Hamad Medical Corporation
Cardiac Transplant Rejection
A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection.
This pilot study aims to assess whether 18F-FDG PET CT imaging has the potential in diagnosing cardiac rejection. The investigators aim to recruit 20 heart transplant subjects within two groups of 10 subjects each.
- Trial name
- NCT06519240
- Testing
- 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.